← Back to all trials
Recruiting
NCT07243171
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Conditions: Overweight and/or Obesity, Weight Management
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE1, PHASE2
Enrollment: 126
Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Location: China-Japan Friendship Hospital Beijing Beijing Municipality
Summary
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
Eligibility Criteria
Inclusion Criteria:
1. At the time of informed consent, with BMI in the range of 24.0 to 35.0 kg/m2 (including the threshold), body weight \>60.0 kg for male, and weight \>50.0 kg for female;
2. Self-declaration of body weight change \
Source: ClinicalTrials.gov (NCT07243171). StuddyBuddy aggregates publicly available trial information.
